WALTHAM, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space and Collagen Solutions plc (AIM:COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, today announced the execution of a supply agreement between Histogenics and Collagen Solutions (UK) Ltd.
The supply agreement will encompass additional collagen material sources for use in Histogenics’ investigational product candidate, NeoCart®, a regenerative medicine product currently in Phase 3 clinical trials using autologous cell therapy, biomaterials and engineering to develop a tissue implant to repair knee cartilage damage. The supply agreement may also encompass additional future products in the Histogenics pipeline for use in markets outside of the United States.
Commenting on the agreement Dr Stewart White, CEO of Collagen Solutions, said: “Collagen Solutions has again demonstrated that it can provide materials which add real value to the delivery of novel regenerative therapies such as NeoCart®, which is a novel product that is synergistic with ChondroMimetic, the product which Collagen Solutions recently acquired. We are very pleased to be part of the Histogenics journey and look forward to participating in an exciting future with Adam and the team in Boston.”
Adam Gridley, CEO of Histogenics, added: “We are pleased to enter into this partnership with Collagen Solutions in the United Kingdom as they have the historical know-how, leading technical capabilities and unique technology platforms that will provide additional supply capabilities in the United States and potentially serve our future product development requirements for new indications and for our markets outside of the U.S. We have been looking for a collaboration partner for some time to augment our internal primary collagen supply chain capabilities for NeoCart, which remain on track. Stewart and the team at Collagen Solutions fit our criteria perfectly, and we look forward to building upon our partnership to potentially provide patients with exciting new biologic therapeutics for the treatment of cartilage defects.”
Histogenics is a regenerative medicine company focused on developing and commercialising products in the musculoskeletal segment of the marketplace. The regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bio-adhesives and growth factors to provide solutions that can be utilised individually or in concert to treat musculoskeletal-related conditions. The first product candidate, NeoCart®, leverages the platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.